Roche to buy cancer diagnostic firm BioImagene Inc for $100 million

Swiss global health-care company, Roche Holding AG yesterday said that it has agreed to buy US-based cancer diagnostic firm BioImagene Inc, for around $100 million to further strengthen its tissue-based cancer diagnostics and research.

Swiss drug giant Roche, based in Basel, is the world leader in in-vitro diagnostics and drugs for cancer and BioImagene is an innovative leader in the field of digital pathology workflow and analysis.

Digital pathology is a suite of dynamic, image-based technologies that enable image capture, information management, image analysis and virtual sharing of patients' tissue samples on glass slides.

BioImagene, a privately held company based in Sunnyvale, California provides innovative digital pathology solutions for the anatomic pathology laboratory. The company is in the business of cancer diagnosis, detection and therapy selection.

BioImagene's products create high-resolution, whole-slide digital images from glass microscope slides. They also provide the software to view, analyze and manage tissue images using a computer, taking pathology beyond traditional microscope applications.

In addition, their products improve workflow efficiency in image archiving and retrieval, remote case review, and turnaround time.

Roche said that the acquisition is being made through its wholly owned Arizona-based subsidiary Ventana Medical Systems Inc.